Polygenic familial hypercholesterolaemia: Does it matter?

The Lancet

Volumn 381, Issue 9874, 2013, Pages 1255-1257

  Stein, Evan A ^a   Raal, Frederick J ^b  

^a Metabolic and Atherosclerosis Research Center   (United States)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN B100; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; FAMILIAL HYPERCHOLESTEROLEMIA; FAMILY HISTORY; GENE MUTATION; HEART DISEASE; HUMAN; NOTE; PHENOTYPE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84876161625     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)60187-7     Document Type: Note

References (16)

1. Goldstein J, Hobbs H, Brown M. Familial hypercholesterolemia. In: Scriver C, Beauder A, Sly W, Valle D, eds. The metabolic and molecular bases of inherited disease. New York: McGraw-Hill, 2001: 2863-13.
2. Usifo E, Leigh SE, Whittall RA, et al. Low-density lipoprotein receptor gene familial hypercholesterolemia variant database: update and pathological assessment. Ann Hum Genet 2012; 76: 387-401.
3. Slack J. Risks of ischaemic heart disease in familial hyperlipoproteinaemic states. Lancet 1969; 2: 1380-82.
4. Müller C. Xanthomata, hypercholesterolemia and angina pectoris. Acta Med Scand 1938; 89: 75-84.
5. Scientific Steering Committee on behalf of the Simon Broome Register Group. Mortality in treated heterozygous familial hypercholesterolemia: implications for clinical management. Atherosclerosis 1999; 42: 105-12.
6. lllingworth DR, Sexton GJ. Hypercholesterolemic effects of mevinolin in patients with heterozygous familial hypercholesterolemia. J Clin Invest 1984; 74: 1972-78.
7. Ellis A, Zhou R, Stein EA. effect of lipid-lowering treatment on natural history of heterozygous familial hypercholesterolemia in past three decades. Am J Cardiol 2011; 108: 223-26.
8. Wierzbicki AS, Humphries SE, Minhas R. Familial hypercholesterolaemia: summary of NICE guidance. BMJ 2008; 337: a1095.
9. Talmud PJ, Shah S, Whittall R, et al. Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study. Lancet 2013; published online Feb 22. http://dx.doi.org/10.1016/S0140-6736(12)62127-8.
10. Ference BA, Yoo W, Alesh I, et al. effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a mendelian randomization analysis. J Am Coll Cardiol 2012; 60: 2631-39.
11. Schmidt HH, Hill S, Makariou EV, Feuerstein IM, Dugi KA, Hoeg JM. Relation of cholesterol-year score to severity of calcific atherosclerosis and tissue deposition in homozygous familial hypercholesterolemia. Am J Cardiol 1996; 77: 575-80.
12. Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 2012; 380: 572-80.
13. Ferrieres J, Lambert J, Lussier-Cacan S, Davignon J. Coronary artery disease in heterozygous familial hypercholesterolemic patients with the same LDL receptor gene mutation. Circulation 1995; 92: 290-95.
14. Pimstone SN, Sun XM, du Souich C, et al. Phenotypic variation in heterozygous familial hypercholesterolemia: a comparison of Chinese patients with the same or similar mutations in the LDL receptor gene in China or Canada. Arterioscler Thromb Vasc Biol 1998; 18: 309-15.
15. Kajinami K, Takekoshi N, Brousseau ME, Schaefer EJ. Pharmacogenetics of HMG-CoA reductase inhibitors: exploring the potential for genotype-based individualization of coronary heart disease management. Atherosclerosis 2004; 177: 219-34.
16. Starr B, Hadfield SG, Hutten BA, et al. Development of sensitive and specific age-and gender-specific low-density lipoprotein cholesterol cutoffs for diagnosis of first-degree relatives with familial hypercholesterolaemia in cascade testing. Clin Chem Lab Med 2008; 46: 791-803.